The role of biomarkers and molecular profiling in cancer diagnosis and treatment continues to expand. In oncology, a biomarker can indicate cancer type, how a cancer will progress if left untreated, what specific treatment may be most effective for a given cancer, and how well treatment is working over time. For five of the most common types of cancer (lung, prostate, colorectal, breast, and skin), there are more than 75 biomarkers used in clinical practice. The sheer number of treatment options across tumor types and the complexity of delivering care makes it difficult for cancer care providers to integrate new therapeutics, like biomarker testing, into their practices.
Barriers to using biomarker testing are common. Respondents to ACCC’s 2018 Trending Now in Cancer Care Survey indicate that insurance coverage, reimbursement, and insufficient protocols are among the issues working against the widespread implementation of biomarker testing in oncology practices.
To help cancer care providers surmount these and other barriers and enhance their knowledge of this rapidly evolving treatment area, ACCC launched the first phase of BiomarkerLIVE in April 2019. Since then, ACCC has worked with clinical experts and industry leaders to develop a common lexicon of biomarker terminology to promote better communication among cancer care teams; establish a resource library of materials relevant to cancer biomarkers and biomarker testing; and host a how-to webinar that explores how cancer programs can use these tools to implement effective biomarker testing protocols for their patients.
Building on the success of BiomarkerLIVE’s launch, Phase 2 will help cancer providers better understand what is needed to facilitate the integration of precision medicine into everyday practice. The objective of this phase is twofold:
Webinar topics include biomarker basics, inherited cancers, laboratory medicine, cost and coverage, and tumor-specific case examples.
Addresses the role of laboratory medicine professionals and pathologists in biomarker testing, incorporating a review of testing techniques and applications, lab-specific regulations, and the impact of those regulations on biomarker testing.
We will review current policies and regulations that drive costs related to biomarker testing.
Deep dive into the differences between germline and somatic mutations, with case examples, and presentation of findings from the LUNGevity/FORCE patient survey.
Introduction to cancer biomarkers, relevant terminology, and implications for cancer care.
Presented at the 2020 ASCO Virtual Scientific Program
Biomarker Testing in Practice: Process Improvement Toolkit
Review the four key elements needed when developing a precision medicine program that successfully incorporates biomarker testing.
Application of Biomarkers in Clinical Trials
This white paper details considerations when determining to conduct biomarker testing on a patient, and the role the test results may play in potentially making that patient eligible for future clinical trials.
Biomarker testing is crucial to precision medicine, but barriers still exist. Learn from two healthcare advocates about recent policy changes designed to ensure better access to biomarker testing.
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
BiomarkerLIVE Project from the Association of Community Cancer Centers Supports Providers in Integration of Precision Medicine into Everyday Practice
April 29, 2020